FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113664107> ?p ?o ?g. }

• W2113664107 endingPage "2545" @default.
• W2113664107 startingPage "2540" @default.
• W2113664107 abstract "ABSTRACT The Infectious Diseases Society of America advocates trimethoprim-sulfamethoxazole (SXT) as initial therapy for females with acute uncomplicated bacterial cystitis in settings where the prevalence of SXT resistance does not exceed 10 to 20%. To determine trends in the activities of SXT, ampicillin, ciprofloxacin, and nitrofurantoin among urine isolates of Escherichia coli from female outpatients, susceptibility testing data from The Surveillance Network (TSN) Database-USA ( n = 286,187) from 1995 to 2001 were analyzed. Resistance rates among E. coli isolates to ampicillin (range, 36.0 to 37.4% per year), SXT (range, 14.8 to 17.0%), ciprofloxacin (range, 0.7 to 2.5%), and nitrofurantoin (range, 0.4 to 0.8%) varied only slightly over this 7-year period. Ciprofloxacin was the only agent studied that demonstrated a consistent stepwise increase in resistance from 1995 (0.7%) to 2001 (2.5%). In 2001, SXT resistance among E. coli isolates was >10% in all nine U.S. Bureau of the Census regions. At institutions testing ≥100 urinary isolates of E. coli ( n = 126) in 2001, ampicillin (range, 27.3 to 98.8%) and SXT (range, 7.5 to 47.1%) resistance rates varied widely while ciprofloxacin (range, 0 to 12.9%) and nitrofurantoin (range, 0 to 2.8%) resistance rates were more consistent. In 2001, the most frequent coresistant phenotypes were resistance to ampicillin and SXT (12.0% of all isolates; 82.3% of coresistant isolates) and resistance to ampicillin, ciprofloxacin, and SXT (1.4% of all isolates; 9.9% of coresistant isolates). Coresistance less frequently included resistance to nitrofurantoin (3.5% of coresistant isolates) than resistance to ciprofloxacin (15.8%), SXT (95.7%), and ampicillin (98.1%). In conclusion, among urinary isolates of E. coli from female outpatients in the United States, national resistance rates to SXT were relatively consistent (14.8 to 17.0%) from 1995 to 2001 but demonstrated considerable regional and institutional variation in 2001. Therapies other than SXT may need to be considered in some locations." @default.
• W2113664107 created "2016-06-24" @default.
• W2113664107 creator A5038009031 @default.
• W2113664107 creator A5038353955 @default.
• W2113664107 creator A5059192444 @default.
• W2113664107 creator A5061522332 @default.
• W2113664107 creator A5091128796 @default.
• W2113664107 date "2002-08-01" @default.
• W2113664107 modified "2023-09-27" @default.
• W2113664107 title "Trends in Antimicrobial Resistance among Urinary Tract Infection Isolates of <i>Escherichia coli</i> from Female Outpatients in the United States" @default.
• W2113664107 cites W1964168847 @default.
• W2113664107 cites W1965833435 @default.
• W2113664107 cites W1989051873 @default.
• W2113664107 cites W1995013130 @default.
• W2113664107 cites W2013637885 @default.
• W2113664107 cites W2017210944 @default.
• W2113664107 cites W2037554663 @default.
• W2113664107 cites W2040443954 @default.
• W2113664107 cites W2040452640 @default.
• W2113664107 cites W2042166722 @default.
• W2113664107 cites W2052392350 @default.
• W2113664107 cites W2052619562 @default.
• W2113664107 cites W2073144086 @default.
• W2113664107 cites W2074043102 @default.
• W2113664107 cites W2079785911 @default.
• W2113664107 cites W2088906839 @default.
• W2113664107 cites W2101388903 @default.
• W2113664107 cites W2103703835 @default.
• W2113664107 cites W2104133434 @default.
• W2113664107 cites W2113206822 @default.
• W2113664107 cites W2117115851 @default.
• W2113664107 cites W2119643139 @default.
• W2113664107 cites W2127286950 @default.
• W2113664107 cites W2142909774 @default.
• W2113664107 cites W2159346370 @default.
• W2113664107 cites W2161630897 @default.
• W2113664107 cites W2170027182 @default.
• W2113664107 doi "https://doi.org/10.1128/aac.46.8.2540-2545.2002" @default.
• W2113664107 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/127340" @default.
• W2113664107 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12121930" @default.
• W2113664107 hasPublicationYear "2002" @default.
• W2113664107 type Work @default.
• W2113664107 sameAs 2113664107 @default.
• W2113664107 citedByCount "356" @default.
• W2113664107 countsByYear W21136641072012 @default.
• W2113664107 countsByYear W21136641072013 @default.
• W2113664107 countsByYear W21136641072014 @default.
• W2113664107 countsByYear W21136641072015 @default.
• W2113664107 countsByYear W21136641072016 @default.
• W2113664107 countsByYear W21136641072017 @default.
• W2113664107 countsByYear W21136641072018 @default.
• W2113664107 countsByYear W21136641072019 @default.
• W2113664107 countsByYear W21136641072020 @default.
• W2113664107 countsByYear W21136641072021 @default.
• W2113664107 countsByYear W21136641072022 @default.
• W2113664107 countsByYear W21136641072023 @default.
• W2113664107 crossrefType "journal-article" @default.
• W2113664107 hasAuthorship W2113664107A5038009031 @default.
• W2113664107 hasAuthorship W2113664107A5038353955 @default.
• W2113664107 hasAuthorship W2113664107A5059192444 @default.
• W2113664107 hasAuthorship W2113664107A5061522332 @default.
• W2113664107 hasAuthorship W2113664107A5091128796 @default.
• W2113664107 hasBestOaLocation W21136641072 @default.
• W2113664107 hasConcept C104317684 @default.
• W2113664107 hasConcept C183641309 @default.
• W2113664107 hasConcept C2776021129 @default.
• W2113664107 hasConcept C2777629877 @default.
• W2113664107 hasConcept C2778512257 @default.
• W2113664107 hasConcept C2779425571 @default.
• W2113664107 hasConcept C2780728791 @default.
• W2113664107 hasConcept C42972112 @default.
• W2113664107 hasConcept C4937899 @default.
• W2113664107 hasConcept C501593827 @default.
• W2113664107 hasConcept C547475151 @default.
• W2113664107 hasConcept C55493867 @default.
• W2113664107 hasConcept C71924100 @default.
• W2113664107 hasConcept C86803240 @default.
• W2113664107 hasConcept C89423630 @default.
• W2113664107 hasConcept C94665300 @default.
• W2113664107 hasConceptScore W2113664107C104317684 @default.
• W2113664107 hasConceptScore W2113664107C183641309 @default.
• W2113664107 hasConceptScore W2113664107C2776021129 @default.
• W2113664107 hasConceptScore W2113664107C2777629877 @default.
• W2113664107 hasConceptScore W2113664107C2778512257 @default.
• W2113664107 hasConceptScore W2113664107C2779425571 @default.
• W2113664107 hasConceptScore W2113664107C2780728791 @default.
• W2113664107 hasConceptScore W2113664107C42972112 @default.
• W2113664107 hasConceptScore W2113664107C4937899 @default.
• W2113664107 hasConceptScore W2113664107C501593827 @default.
• W2113664107 hasConceptScore W2113664107C547475151 @default.
• W2113664107 hasConceptScore W2113664107C55493867 @default.
• W2113664107 hasConceptScore W2113664107C71924100 @default.
• W2113664107 hasConceptScore W2113664107C86803240 @default.
• W2113664107 hasConceptScore W2113664107C89423630 @default.
• W2113664107 hasConceptScore W2113664107C94665300 @default.
• W2113664107 hasIssue "8" @default.
• W2113664107 hasLocation W21136641071 @default.
• W2113664107 hasLocation W21136641072 @default.

• next